ANDA 89069, held by Hospira. Procainamide Hydrochloride.
As of Nov 21, 2026, ANDA 89069 (Procainamide Hydrochloride), held by Hospira, was first approved by FDA on Feb 12, 1986, with 13 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 12, 1986 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Procainamide Hydrochloride100MG/ML · injectable;injection | Procainamide Hydrochloride | Rx |
| May 5, 1999 | Supplement 16Labeling | Approved | None posted |
| Dec 21, 1998 | Supplement 10Labeling | Approved | None posted |
| Jun 8, 1998 | Supplement 14Manufacturing | Approved | None posted |
| Jun 8, 1998 | Supplement 12Manufacturing | Approved | None posted |
| May 5, 1998 | Supplement 11Manufacturing | Approved | None posted |
| Feb 12, 1998 | Supplement 13Labeling | Approved | None posted |
| Aug 24, 1994 | Supplement 8Manufacturing | Approved | None posted |
| Dec 21, 1993 | Supplement 7Manufacturing | Approved | None posted |
| Nov 22, 1991 | Supplement 6Labeling | Approved | None posted |
| Aug 13, 1991 | Supplement 5Labeling | Approved | None posted |
| Jan 28, 1991 | Supplement 4Labeling | Approved | None posted |
| Nov 23, 1988 | Supplement 2Labeling | Approved | None posted |
| Aug 12, 1988 | Supplement 3Labeling | Approved | None posted |
| Feb 12, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters